Acorda Announces Positive Vote by FDA Advisory Committee for Fampridine-SR

Wed, Oct 14, 2009 * Committee Views Fampridine-SR as Safe, Effective and Clinically Meaningful for Improving Walking in People with Multiple Sclerosis * Conference Call Scheduled for [...]

• Caroline says: Acorda had a special advisory board meeting requested by the FDA to discuss side effect issues in doses above 10mg. The outcome was positive for Acorda: in 10mg doses the drug appears safe and it helps people walk.
   

• Fampridine-SR Receives Priority FDA Review for Walking Drug

  Acorda’s shares up sharply on news of FDA priority review for Fampridine-SR in multiple sclerosis Mark Todoruk Shares in Acorda Therapeutics soared as much as 28 percent [...]

  • Caroline says: Fampridine-SR has received priority review from the FDA, meaning it could be approved as early as this year, and will launch shortly thereafter. Studies showed fampridine-SR in patients with MS improved walking speed.